|
Age ≥ 50 years
|
1.18
|
(0.78, 1.78)
|
0.434
|
|
ECOG performance status
| | | |
|
2 – 3 versus 0 – 1
|
1.15
|
(0.76, 1.76)
|
0.507
|
|
Hydroxyproline/creatinine ratio (centered)
|
1.06
|
(1.02, 1.10)
|
0.001
|
|
Bone-specific alkaline phosphatase (U/L)
|
1.00
|
(0.99, 1.01)
|
0.471
|
|
Estrogen-receptor status versus negative
| | | |
|
Positive
|
0.78
|
(0.44, 1.40)
|
0.406
|
|
Unknown
|
1.53
|
(0.67, 3.50)
|
0.314
|
|
Progesterone-receptor status versus negative
| | | |
|
Positive
|
0.58
|
(0.33, 1.00)
|
0.050
|
|
Unknown
|
0.51
|
(0.24, 1.07)
|
0.074
|
|
Sites of metastasis (yes versus no)
| | | |
|
Bone as only metastatic site
|
0.75
|
(0.44, 1.29)
|
0.301
|
|
Lung
|
1.49
|
(0.733, 3.01)
|
0.273
|
|
Liver
|
0.84
|
(0.435, 1.61)
|
0.593
|
|
Time from diagnosis of bone metastases to study entry, years
|
1.21
|
(1.05, 1.38)
|
0.008
|
|
Time from cancer diagnosis to study entry, years
|
0.83
|
(0.72, 0.95)
|
0.008
|
|
Lesion characteristics and numbers
| | | |
|
≥ 3 osteolytic versus < 3 osteolytic
|
1.34
|
(0.92, 1.95)
|
0.128
|
|
1 – 2 osteoblastic versus no osteoblastic
|
1.19
|
(0.74, 1.92)
|
0.471
|
|
≥ 3 osteoblastic versus no osteoblastic
|
0.79
|
(0.36, 1.74)
|
0.559
|
|
1 – 2 mixed versus no mixed
|
0.64
|
(0.36, 1.16)
|
0.140
|
|
≥ 3 mixed versus no mixed
|
0.63
|
(0.35, 1.12)
|
0.112
|
|
Prior fracture (yes versus no)
|
0.99
|
(0.58, 1.67)
|
0.964
|
|
Pain scores (centered)
|
1.03
|
(0.96, 1.11)
|
0.406
|
|
Prior chemotherapy (yes versus no)
|
1.54
|
(0.46, 5.16)
|
0.484
|
|
≥ 2 prior hormonal therapies (yes versus no)
|
1.61
|
(1.08, 2.40)
|
0.020
|
|
Prior radiotherapy (yes versus no)
|
0.75
|
(0.47, 1.20)
|
0.230
|
